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The enormous diversity of HIV-1 presents a formidable challenge for developing an effective AIDS
vaccine. In this issue of Cell, Barouch et al. show that bioinformatically designed antigens, pieced
together from multiple HIV immune epitopes, partially protect rhesus macaques from simian-
human immunodeficiency virus infection. This ‘‘mosaic’’ approach holds promise for the develop-
ment of broadly protective vaccines.Development of an effective AIDS vaccine
has proven a daunting task and yielded
disappointing results for many years.
Recently, however, some exciting prog-
ress has been made. The RV144 (or
Thai) trial provided the first evidence that
vaccination may lower the risk of
acquiring HIV-1 infection (Rerks-Ngarm
et al., 2009). Although the protective
effects were marginal, this finding revital-
ized the field. Furthermore, novel powerful
techniques have allowed the character-
ization of a substantial number of highly
potent broadly neutralizing antibodies
(Klein et al., 2013). Nonetheless, the in-
duction of immune responses that are
effective against the highly diverse HIV-1
strains circulating worldwide still repre-
sents a major challenge. The report by
Barouch et al. (2013) in this issue of Cell
takes a step toward overcoming the
obstacle of strain diversity, showing that
an HIV-1 mosaic vaccine partially pro-
tects rhesusmacaques against the acqui-
sition and pathogenic effects of a simian-
human immunodeficiency virus, termed
SHIV-SF162P3.
Any vaccine approach aiming for global
protection against HIV/AIDS must find
someway to counter viral sequence diver-
sity. Potential strategies under exploration
include the development of regional,
clade-specific HIV-1 vaccines and the in-
duction of immune responses against
highly conserved viral epitopes. However,
the first approach is complicated because
it requires the development, application,
and approval of multiple effective vac-
cines, and the latter has thus far failed to
induce broadly protective responses.Another strategy being developed is the
use of sequence information from globally
circulating virus strains to design a com-
posite HIV-1 vaccine based on a limited
number of so called ‘‘mosaic’’ sequences.
Mosaic antigens are generated by bio-
informatically integrating regions of natu-
ral HIV-1 sequence that contain a
maximum of potential T cell epitopes
(Fischer et al., 2007). The resulting
polyvalent synthetic vaccines cover the
sequence diversity of thousands of pep-
tides, thereby enabling the delivery of a
diverse range of epitopes with a single
vaccine shot. As anticipated, mosaic anti-
gens induce broader cellular and humoral
immune responses than conventional
wild-type or consensus HIV-1 antigens
(Barouch et al., 2010; Santra et al.,
2010). However, whether or not mosaic
vaccines exert any protective effects
in vivo remained to be determined.
To address this question, the authors
used bivalent (i.e., two variants of) mosaic
antigens containing HIV-1 gag, pol, and
env sequences inserted into replication-
defective adeno (AD) or modified vaccinia
Ankara (MVA) vectors for immunization by
a prime-boost approach (outlined in
Figure 1). Six rounds of rectal challenge
with a heterologous, difficult-to-neutralize
hybrid simian-human immunodeficiency
virus, SHIV-SF162P3, simulated sexual
exposure. Immunization with the mosaic
vaccine did not confer complete protec-
tion or ‘‘sterilizing’’ immunity but reduced
the risk of SHIV infection per intrarectal
challenge by about 90%. This effect is
impressive as the infectious viral dose
was substantially higher than those typi-Cell 155cally encountered during sexual exposure
to HIV-1 in humans. Importantly, 5 of 12
control animals, but none of the vacci-
nated macaques, had died from simian
AIDS by 9 months postchallenge. Thus,
treatment with mosaic HIV-1 antigens
protected the animals against both the
acquisition of SHIV infection and develop-
ment of fatal disease.
These protective effects are particularly
remarkable because the challenge virus
encodes the Gag and Pol proteins of SIV-
mac239,whichdonot cross-reactwith the
HIV-1mosaicGag andPol immunogens in
the vaccine. On the one hand, this limits
the significance of the study because it
does not allow evaluation of the contribu-
tion of Gag- and Pol-directed cellular
immune responses to virological control.
On the other hand, this makes the results
even more intriguing because they sug-
gest that Env-specific immune responses
alone confer significant protection against
the pathogenic outcome of infection.
Peak and set-point viral loads were only
modestly reduced in the vaccinated ani-
mals. However, Gag-specific cellular im-
mune responses would most likely greatly
increase virological control of wild-type
HIV-1 strains. In fact, HIV-1 mosaic anti-
gens were shown previously to induce
particularly broad and effective cellular
immune responses (Barouch et al., 2010;
Santra et al., 2010), and similar prime-
boost vaccine regimens using SIV anti-
gens reduced the set point viral loads by
more than two orders of magnitude (Bar-
ouch et al., 2012). Currently, it is not
possible to determine the effects of HIV-1
Gag- and Pol-specific immune responses, October 24, 2013 ª2013 Elsevier Inc. 495
Figure 1. Protection of Rhesus Macaques Vaccinated with HIV-1
Mosaic Immunogens
In silico optimization of mosaic HIV-1 M Gag/Pol/Env immunogens was per-
formed to maximize coverage of potential T cell epitopes. Healthy rhesus
macaques (green) were primed using adenoviral vector regimens expressing
bivalent mosaic immunogens. At week 12, animals were boosted with either
Adenoviral (Ad) or modified vaccine Ankara (MVA) vector regimens. Starting
52 weeks postimmunization, repetitive intrarectal challenges with chimeric
SHIV-SF162P3 were performed to evaluate vaccine-mediated protection.
Infection of immunized animals (indicated in orange) was delayed, and no
AIDS-related mortality was observed, whereas 5 out of 12 nonimmunized
animals died (red).in nonhuman primate models.
However, expanded under-
standing of the determinants
of host specificity may allow
the generation of simian-
tropicHIV-1strains containing
minimal portions of SIV se-
quences for direct efficacy
testing of HIV-1 Gag-Pol CTL
responses in macaques (Hat-
ziioannou and Evans, 2012).
Notably, Barouch and col-
leagues identified several
correlates of protection, in-
cluding low levels of neutral-
izing antibodies in sera from
vaccinated macaques, anti-
body-dependent complement
deposition, and antibody-
dependent cellular phagocy-
tosis, indicating a contribution
of both neutralizing and
nonneutralizing antibody re-
sponses to the protective ef-
fects. Env-specific antibodies
were also identified asa corre-
late of protection in the RV144
clinical vaccine trial (Haynes
et al., 2012). In contrast to the
human trial, however, Bar-
ouch and coworkers did not
find evidence for a protective
role of antibodies directed
against the V2 loop in HIV-1
Env. Altogether, the mecha-
nisms underlying the protec-
tive effects in the present
study seem to be complex
and remain to be fully defined.
Although the results pre-
sented in Barouch et al.(2013) are exciting, they come with an
important caveat. Themain goal ofmosaic
HIV-1 vaccines is to induce broad immune
responses that are effective against the
highly diverse HIV-1 strains circulating
worldwide. Yet, only a single SHIV strain
was utilized in the present study, and it
therefore does not clarify whether mosaic
antigens confer protection against
different HIV-1 strains. It is encouraging,
however, that the SHIV-SF162P3 chal-
lenge virus seems to be highly stringent.
SHIVs utilized in previous studies typically
expressed easy-to-neutralize tier 1 Env
proteins were frequently spontaneously
controlled and usually did not induce dis-
ease. In contrast, the SHIV-SF162P3 virus496 Cell 155, October 24, 2013 ª2013 Elseviutilized in the present study shows a diffi-
cult-to-neutralize tier 2 phenotype, main-
tains high set point viral loads in most
control animals (>5 logs of viral RNA
copies/ml), and, perhaps most impor-
tantly, was associated with rapid progres-
sion to simian AIDS in 5 of 12 control
animals. The finding that the mosaic vac-
cine inducedsignificant protectionagainst
an apparently highly stringent challenge
virus suggests that it may also be effective
against highly pathogenic HIV-1 strains in
human trials, although it will be important
to further examine the breadth of the pro-
tective effects in future studies once suit-
able additional stringent challenge strains
have been identified.er Inc.Many important questions
remain. What kind of efficacy
can be expected for mosaic
HIV vaccines in humans in
whom the viral doses encoun-
tered during sexual exposures
to HIV-1 are usually substan-
tially lower than those used in
the present study? Will semen
that is present during most
sexual transmissions of HIV-1
and increases its infectious-
ness (Mu¨nchet al., 2007) affect
the protective effects? As no
complete protection was
achieved by immunization, it
will also be important to clarify
whether viral escape variants
that cause disease may
emerge in the long term. These
andotherquestionson theeffi-
cacy ofmosaicHIV-1 vaccines
can only be addressed in hu-
mans, and testing of this
concept in clinical trials seems
highly warranted.ACKNOWLEDGMENTS
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Classic studies proposed that stochastic variability (‘‘noise’’) can drive biological fate switching,
enhancing evolutionary success. Now, Ho et al. report that HIV’s reactivation fromdormant (latently
infected) patient cells—the major barrier to an HIV cure—is inherently stochastic. Eradicating an
incompletely inducible (probabilistic) viral phenotype will require inventive approaches.From tiny viruses to complex vertebrates,
biological systems share a common chal-
lenge to preserve reproductive fitness in
unpredictable, changing environments.
Faced with environmental variability,
many organisms evolve complex sensor-
actuators to continually gauge their sur-
roundings and deterministically adapt.
But, 50 years ago, Dan Cohen proposed
an alternate solution: if organisms could
stochastically generate a range of pheno-
types in each environment, they could
‘‘hedge their bets’’ in much the same
way that financial houses diversify their
assets to minimize risk against economic
crashes. In desert annuals, where repro-
ductive success is governed by unpre-
dictable weather patterns, Cohen noted
that fitness could be enhanced if chance
governed each seed’s fate to germinate
or hibernate (e.g., when the husk thick-
ness of each seed is allowed to stochasti-
cally vary). With some seeds randomly
entering dormancy whatever the environ-
ment, the annuals are always left with a
long-lived subpopulation to avoid extinc-
tion during unforeseen droughts. Butwhat molecular mechanism would allow
organisms to probabilistically generate
the needed cell-to-cell variability? Years
later, studies of active-versus-dormant
infection (i.e., lysis-lysogeny) in the bacte-
rial virus phage l suggested an answer:
noisy gene expression (Arkin et al.,
1998). Gene expression is, in fact, inher-
ently stochastic, subject to random fluc-
tuations in regulating enzymes, mRNAs,
and other biomolecules. These diffusion-
drivenmolecular fluctuations are unavoid-
able at the single-cell level and appear
sufficient to shift cells between transcrip-
tional on and off states (Raj and van
Oudenaarden, 2008). With some cells
randomly active and others dormant, the
result is a distribution of cell fates across
a population. A similar distribution of cell
fates may now have been found in HIV
patients in the clinic. In this issue of Cell,
Ho and colleagues (Ho et al., 2013) report
that HIV’s reactivation from lifelong
dormant (i.e., ‘‘latent’’) reservoirs is
stochastic, likely interfering with persis-
tent therapeutic efforts to activate and
purge this problematic reservoir.The theory that stochastic noise is
sufficient to drive cell-fate decisions has
been demonstrated in a range of bio-
logical systems, from bacteria to verte-
brates (Bala´zsi et al., 2011). Nevertheless,
the theory has faced stiff challenge.
Alternative hypotheses have argued
that hidden deterministic variables, for
example the state of the host cell during
viral infection or the number of infecting
viruses, have a larger impact on eventual
cell-fate (St-Pierre and Endy, 2008; Zeng
et al., 2010). Unknown and unmeasured,
these variables might strongly differ be-
tween the disparate cellular phenotypes,
in fact predicting the seeming stochastic-
ity. Ever finer and more expansive mea-
surements, it appeared, would be needed
to rule out deterministic explanations.
Unexpectedly, a new chapter may now
come from a clinical angle. Much like
bacteriophage l, when HIV infects a cell,
two outcomes are possible. After HIV
integrates its proviral DNA into the
genome of CD4+ T cells, either it enters
a state of active replication killing the cell
or it enters a long-lived latent state where, October 24, 2013 ª2013 Elsevier Inc. 497
